Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the …

Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised
questions about their preferential association with the hallmark pathologies of Alzheimer …

Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer…

Background Plasma biomarkers for Alzheimer’s disease (AD) have broad potential as
screening tools in primary care and disease-modifying trials. Detecting elevated amyloid-β (Aβ) …

Introduction Direct comparisons of the main blood phosphorylated tau immunoassays in
memory clinic populations are needed to understand possible differences. Methods In the …

Background Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate
biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are seen …

Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD)
patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic …

Background The diagnosis of symptomatic Alzheimer's disease is a clinical challenge in adults
with Down syndrome. Blood biomarkers would be of particular clinical importance in this …